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Abstract
Background:  An accurate test for Mycobacterium tuberculosis infection is urgently needed in
immunosuppressed populations. The aim of this study was to investigate the diagnostic power of enzyme-
linked immunospot (ELISPOT)-based IFN-γ release assay in detecting active and latent tuberculosis in HIV-
infected population in bacillus Calmette-Guerin (BCG)-vaccinated area. A total of 100 HIV-infected
individuals including 32 active tuberculosis patients were recruited. An ELISPOT-based IFN-γ release assay,
T-SPOT.TB, was used to evaluate the M. tuberculosis ESAT-6 and CFP-10 specific IFN-γ response.
Tuberculin skin test (TST) was performed for all recruited subjects.
Results:  The subjects were divided into group HIV+ATB (HIV-infected individuals with active
tuberculosis, n = 32), group HIV+LTB (HIV-infected individuals with positive results of T-SPOT.TB assay,
n = 46) and group HIV only (HIV-infected individuals with negative results of T-SPOT.TB assay and without
evidence of tuberculosis infection, n = 22). In group HIV+ATB and HIV+LTB, T-SPOT.TB positive rate in
subjects with TST <5 mm were 50% (16/32) and 41.3% (19/46), respectively. Individuals in group HIV+ATB
and HIV+LTB with CD4+ T cells <500/μl, T-SPOT.TB showed a higher sensitivity than TST (64.5% vs.
22.6% and 62.2% vs. 29.7%, respectively, both P < 0.0001). In addition, the sensitivity of T-SPOT.TB assay
in group HIV+ATB increased to >85% in patients with TB treatment for less than 1 month and CD4+ T
cells ≥200/μl, while for patients treated for more than 3 months and CD4+ T cells <200/μl, the sensitivity
was decreased to only 33.3%. Furthermore, the results could be generated by T-SPOT.TB assay within 24
hours, which was more rapid than TST with 48–72 hours.
Conclusion: ELISPOT-based IFN-γ release assay is more sensitive and rapid for the diagnosis of TB
infection in Chinese HIV-infected individuals with history of BCG vaccination, and could be an effective
tool for guiding preventive treatment with isoniazid in latently infected people and for TB control in China.
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Background
HIV and tuberculosis (TB) are two major infectious killers
of adults in the developing world, and approximately 13
million people are infected with both causative organ-
isms. The world health organization (WHO) estimated
that 0.7 million HIV-positive cases of the 9.2 million (8%
of the total) new cases of TB in 2006 were HIV positive [1].
One-third of the world population harbors Mycobacterium
tuberculosis (M. tuberculosis) in an asymptomatic, latent
form (latent tuberculosis infection, LTBI), about 5–10%
of which develop TB disease during their lifetime, mostly
within 5 years of infection. However, the risk of develop-
ing active TB disease in those that are co-infected with HIV
increases to 5–15% annually, as the immune deficiency
worsens [1,2].
Detection of latent or recent infection, which represents a
reservoir of future tuberculosis cases, offers an opportu-
nity for intensified control [3]. Results of a meta-analysis
suggest that isoniazid preventive therapy (IPT) reduces TB
incidence by 42% overall, or by 60% among individuals
who have positive tuberculin skin test (TST) [4,5]. In HIV-
infected people with LTBI, IPT is an underutilized public
health strategy. However, the skin reaction to tuberculin
purified protein derivative (PPD) is impaired by HIV
infection [6,7]. Furthermore, TST has poor specificity in
areas where bacillus Calmette-Guerin (BCG) is used and
where there is high prevalence of environmental myco-
bacteria [8]. The introduction of interferon (IFN)-γ release
assays (IFNGRAs) using immunogenic and specific M.
tuberculosis antigens (early secreted antigen ESAT-6 and
culture filtrate protein 10 kD CFP-10) for immunodiagno-
sis is therefore a potential advance. Compared with the
TST, studies using IFNGRA demonstrate a high sensitivity
for active tuberculosis [9-11]. Positive scores in these
assays have also been shown in contact studies to equate
well with a history of exposure to tuberculosis [12-14].
Two commercial forms of the IFNGRA are now licensed
for use in the developed world: the T-SPOT.TB (Oxford
Immunotec, Abingdon, UK), which has been developed
based on the enzyme-linked immunospot (ELISPOT)
assay [15]; and the whole blood-based QuantiFERON-TB
Gold (QFT-G; Cellestis, Melbourne, Australia), which
uses an enzyme-linked immunosorbent assay (ELISA) to
detect IFN-γ released into culture supernatant [16].
A prospective study in immunocompetent individuals
showed that T-SPOT.TB and QuantiFERON-TB Gold have
higher specificity than TST. Overall, T-SPOT.TB produced
significantly more positive results (38%, n = 144) than
QuantiFERON-TB Gold (26%, n = 100) (P < 0.0001) [17].
Several comparison studies of T-SPOT.TB with TST indi-
cate that T-SPOT.TB appears to be a better way to identify
M. tuberculosis infection than TST even in a BCG-vacci-
nated population [18,19]. However, the sensitivity and
specificity of T-SPOT.TB in diagnosing M. tuberculosis
infection including active and latent status in HIV-
infected individuals have not been systemically evaluated.
Furthermore, studies in TB pandemic countries are rather
limited. We detected M. tuberculosis infection using TST as
well as T-SPOT.TB assay in 102 HIV-infected individuals
in Yunnan province in China, a region with high preva-
lence of HIV infection due to the drug abuse. The aims of
this study were to determine the diagnostic power of T-
SPOT.TB assay in active and latent M. tuberculosis infec-
tions in HIV-infected population in comparison with TST
and to evaluate the effect of T cell numbers on the sensi-
tivity of the T-SPOT.TB and TST.
Methods
Study population
One hundred and two HIV-infected individuals from
Yunnan province, the HIV and TB pandemic area in
China, were included in this study. HIV infection was con-
firmed by clinical records, routine serum tests (competi-
tive ELISA and Western blotting confirmation) and CD4+
T cell counts. All subjects had a history of newborn BCG
vaccination and were received TST using PPD at enroll-
ment (see figure 1). The study subjects were categorized as
HIV-infected individuals with active tuberculosis
(HIV+ATB), HIV-infected individuals with latent tubercu-
losis infection (HIV+LTB) and HIV-infected individuals
without evidence of tuberculosis infection (HIV only).
Criteria for determining HIV+ATB and HIV+LTB subjects
Since BCG vaccination is still one of the national routine
immunization items and widely implemented in China,
we used T-SPOT.TB assay to distinguish BCG vaccination
from M. tuberculosis infection. The HIV-infected subjects
were diagnosed with active TB (ATB) or latent TB (LTB)
based on T-SPOT.TB assay and extensive clinical evalua-
tion of tuberculosis, including TB contact history, chest x-
ray, sputum smear and culture. The combined T-SPOT.TB
assay and extensive clinical evaluation resulted in the clas-
sification of three groups of human subjects: HIV+ATB,
HIV+LTB and HIV only. Thirty-two patients (22 men and
10 women, 37.0 ± 8.6 years of age, range 26–65 yr) were
defined as having ATB (HIV+ATB) by the presence of
recent clinical symptoms of TB, positive culture of M.
tuberculosis and/or positive smear test for acid-fast bacilli
(AFB) from sputum and abnormal chest radiograph. 46
(24 men and 22 women, 33.9 ± 6.7 years of age, range 24–
45 yr) were diagnosed with latent TB (HIV+LTB) by posi-
tive T-SPOT.TB assay and absence of any active tuberculo-
sis, including clinical manifestations of pulmonary and
extra-pulmonary tuberculosis as well as abnormal chest
radiograph. 22 HIV-infected individuals (9 men and 13
women, 33.7 ± 5.8 years of age, range 22–44 yr) wereBMC Immunology 2009, 10:31 http://www.biomedcentral.com/1471-2172/10/31
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defined as no M. tuberculosis co-infection group (HIV
only) based on negative T-SPOT.TB assay and the absence
of any clinical evidence of tuberculosis.
T-SPOT.TB assay
T-SPOT.TB kit (Oxford Immunote Ltd., Oxford, UK), a
novel commercial ELISPOT assay to detect IFN-γ release
induced by M. tuberculosis ESAT-6 and CFP-10, was
employed to identify M. tuberculosis infection including
latent and active M. tuberculosis infection. The test result of
T-SPOT.TB assay was considered positive if either or both
of Panel A (containing peptide antigens derived from
ESAT-6) or Panel B (containing peptide antigens derived
from CFP-10) had six or more spots than the negative con-
trol, and this number was at least two times greater than
the number of spots in the negative controls according to
the manufacturer's instructions. The spots were read using
the ELISPOT plate reader (AID-Gmb-H, Germany). The
results were double checked by other lab workers and, if
necessary, corrected by manual counting. The laboratory
technicians were blinded to the subject identifiers.
TST
TST was carried out and read by one individual, using the
Mantoux technique on the volar surface of a forearm, with
five tuberculin units (TU) of tuberculin PPD RT23 (Stat-
ens Seruminstitut, Copenhagen, Denmark). Tests were
read at 48–72 h, and were measured with a ruler as indu-
ration diameters along and across the arm.
Data analysis
Statistical analysis was done using the non-parametric
Mann-Whitney test and Fisher's exact test. Significance
was inferred for P < 0.05.
Flow chart showing numbers recruited in HIV-positive (HIV+ve) individuals with or without active tuberculosis Figure 1
Flow chart showing numbers recruited in HIV-positive (HIV+ve) individuals with or without active tuberculo-
sis. TB = tuberculosis; TST = tuberculin skin test; T-SPOT.TB: commercial test IFNGAR from Oxford Immunotec, Abingdon, 
UK.
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Results
Baseline characteristics of enrolled subjects according to 
M. tuberculosis infection status
One hundred and two HIV-infected individuals were
tested. Thirty-two patients with active TB (ATB) and 68
without ATB evidence were recruited. T-SPOT.TB results of
2 individuals without ATB were not available due to logis-
tic problems (i.e. the persons failed to go to the lab for the
test) and were then excluded (Figure 1). Baseline informa-
tion for 100 recruited subjects is shown in Table 1.
Thirty-two HIV positive patients with ATB were assigned
into group HIV+ATB. Nineteen of 32 patients had been
receiving TB treatment with the longest duration of 12
months, while the remaining 13 patients were not treated
with anti-TB drugs upon enrollment. In group HIV+ATB,
21 (65.6%) patients were T-SPOT.TB positive and 8
(25%) were TST positive (P = 0.013) (Figure 1). LTBI was
diagnosed with T-SPOT.TB in individuals without ATB
evidence. Forty-six of 68 were T-SPOT.TB positive and
assigned into group HIV+LTB. The remaining 22 with neg-
ative T-SPOT.TB test were named as group HIV only (Fig-
ure 1). Based on CD4+ T cell count, the subjects in these
3 groups were divided into 3 subgroups: CD4+ T cells
<200/μl, 200–500/μl and >500/μl. At recruitment, TST
results were read and recorded individually by one
observer.
Comparison of T-SPOT.TB with TST results in groups 
HIV+ATB and HIV+LTB
We divided the subjects in both groups into different sub-
groups respectively based on the TST diameter: 0–4 mm,
5–9 mm, 10–14 mm and >15 mm (Figure 2). In group
HIV+ATB, 21 of 32 (65.6%) were T-SPOT.TB positive,
whereas TST positive rate was only 15.6% (5/32) (P <
0.005). Among 11 T-SPOT.TB negative patients, 7 were
with CD4+ T cells <200/μl and 4 with CD4+ T cells 200–
500/μl. In 24 TST negative patients, 16 had CD4+ T cells
<200/μl and 8 with CD4+ T cells 200–500/μl.
When 5 mm induration was used as the cutoff for TST, 16
of 32 (50%) HIV+ATB patients with negative TST (indura-
tion  ≤4 mm) were positive in T-SPOT.TB assay, while
among HIV+LTB persons, 19/46 (41.3%) with TST ≤4 mm
were T-SPOT.TB positive. Therefore, this portion was mis-
diagnosed by TST in HIV-infected individuals. In subjects
with TST >5 mm, T-SPOT.TB assay did not demonstrate
any advantage of diagnosis compared with TST.
Effect of CD4+ T cell count on T-SPOT.TB assay in HIV 
infected individuals
CD4+ T cell count which represents the immune status or
HIV/AIDS progression of the patients is a key factor in HIV
infected persons that could affect the TB diagnosis. In Fig-
ure 3, the bubbles showed the distribution of CD4+ T cell
count in different groups. In HIV only group, the individ-
uals with CD4+ T cells <200 μl, 200–500/μl and >500/μl
distributed relatively evenly. However in the other two
groups, the patients in different subgroups based on
CD4+ T cell count distributed reversely. CD4+ T cell count
in the majority of the patients in HIV+LTB group was 500/
μl, while most patients in group HIV+ATB were CD4+ T
cells <200/μl, which possibly indicated the role of CD4+
T cells in controlling TB activation and the high risk of
progression from latent infection to active tuberculosis.
In addition, we compared T-SPOT.TB with TST results
according to different CD4+ T cell counts both in patients
with ATB and persons without ATB (Figure 4a, b). In
HIV+ATB patients with CD4+ T cells <200/μl and 200–
500/μl, T-SPOT.TB showed a higher sensitivity than TST
Table 1: Baseline data for all the recruited subjects screened 
with T-SPOT.TB assay and TST
HIV+ATB HIV+LTB HIV only
Patient No. 32 46 22
Age (years)
median (SD)
37.0 (8.6) 33.9 (6.7) 33.7 (5.8)
Male/Female 22/10 26/22 9/13
BCG vaccination history Yes Yes Yes
CD4+ T cell counts, n (%)
<200/μl 21 (65.6) 4 (8.7) 5 (22.7)
200–500/μl 10 (31.3) 19 (41.3) 9 (40.9)
>500/μl 1 (3.1) 23 (50.0) 8 (36.4)
Anti-TB treatment, n (%)
<1 mo 18 (56.3) No No
1–3 mo 9 (28.1)
>3 mo 5 (15.6)
HAART, n (%) 20 (62.5) 4 (8.7) 2 (9.1)
T-SPOT.TB positive rate in group HIV+ATB and HIV+LTB  stratified by indurations of TST (mm) Figure 2
T-SPOT.TB positive rate in group HIV+ATB and 
HIV+LTB stratified by indurations of TST (mm). The 
black column represents the T-SPOT.TB positive rate of 
patients in HIV+ATB group, and the gray column represents 
the T-SPOT.TB positive rate of patients in HIV+LTB group. 
The T-SPOT.TB positive portion with TST 0–4 mm was mis-
diagnosed by TST.
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(both P < 0.0001). Since there was only one patient with
CD4+ T cells >500/μl who was both T-SPOT.TB and TST
positive, it was not compared and included in this sub-
group, which is similar to individuals without ATB. In
subgroup of CD4+ T cells <200/μl and 200–500/μl, T-
SPOT.TB appeared to be a more sensitive assay to diag-
nose LTB than TST (both P < 0.0001). However, no signif-
icant difference was found between the two tests in
individuals with CD4+ T cells >500/μl. These results
strongly suggest that T-SPOT.TB assay markedly increased
TB diagnostic power especially in subjects with CD4+ T
cells <500/μl.
Combined impact of TB treatment and total CD4+ T cells 
on T-SPOT.TB assay
The patients in group HIV+ATB were divided into 3 sub-
groups according to different durations of TB treatment:
<1 month, 1–3 months and > 3 months. IFN-γ responses
to either ESAT-6 or CFP-10 in patients in 3 subgroups
were examined. There was a decreasing tendency of IFN-γ
response with increasing treatment duration in both
CD4+ T cells ≥200/μl and <200/ul subgroups. However,
no significant difference was found. Due to the impact of
TB treatment duration and the total CD4+ T cells on the
positive rate of T-SPOT.TB assay in HIV combined active
tuberculosis infection, we found that the sensitivity of T-
SPOT.TB assay could increase to >85% in the patients
with TB treatment for less than 1 month and CD4+ T cells
≥200/μl, while the sensitivity for patients treated for more
than 3 months and CD4+ T cells < 200/μl was only 33.3%
(Figure 5).
Discussion
TB infection control measures need to be implemented
urgently in high-burden countries, which could have
important global implications. First of all, there is a clear
need a rapid and useful tool to identify TB infection
including both active and latent TB accurately. In China,
TST has low specificity due to mandatory BCG vaccina-
tion, and also low sensitivity especially in immunosup-
pressed (i.e. HIV-1 infection) population. The recently
available M. tuberculosis antigen-specific IFNGRA thus rep-
resents a significant advancement in the field of TB diag-
nostics. Studies confirmed that IFNGRA was more
sensitive and specific than TST and independent of CD4+
T cell count in moderate to advanced HIV infected
humans. Furthermore, the results could be generated by T-
SPOT.TB assay within 24 hours, which was more rapid
The distributions of subjects with different CD4+ T cell counts in HIV only, HIV+LTB, and HIV+ATB groups Figure 3
The distributions of subjects with different CD4+ T cell counts in HIV only, HIV+LTB, and HIV+ATB groups. 
The black bubbles represent CD4+ T cells <200/μl, the gray bubbles represent CD4+ T cells 200–500/μL, and the white bub-
bles represent CD4+ T cells >500/μl. The sizes of the bubbles represent the percentage of patients with appropriate CD4+ T 
cell counts.
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than TST with 48–72 hours. Although T-SPOT.TB assay
was more sensitive than TST, the positive rate of T-
SPOT.TB assay was decreased to only 44.4% in HIV
patients with CD4+ T cells <200/μl, comparing 74.2%
and 67.9% in HIV patients with CD4+ T cells >500/μl and
200–500/μl, respectively. Therefore, in severely immuno-
suppressed individuals, IFNGRA may be impaired by T-
cell anergy [20-22].
There are mutiple factors that may affect IFNGRA, such as
TB treatment and immunosuppression status. Chee et al
concluded that anti-TB treatment had different effect on T-
cell response to ESAT-6 and CFP-10 as measured by T-
SPOT.TB [23]. Wilkins et al found that preventive treat-
ment of LTBI resulted in 1.8 fold average increase in the
number of IFN-γ-producing T cells within 26 ± 4 days, fol-
lowed by a decrease by the end of the treatment period
(82 ± 6 days) [3]. Therefore, we hypothesized that T-
SPOT.TB could serve as an effective indicator of the TB
therapeutic efficacy. In our study, patients in HIV+ATB
group were classified into subgroups according to differ-
ent treatment durations: <1 mo, 1–3 mo and >3 mo. We
found that there was a decreasing tendency of positive T-
SPOT.TB assay with increasing treatment duration. Unfor-
tunately, the difference did not appear to be statistically
significant, perhaps due to the insufficient number of the
recruited subjects. Thus, a larger cohort study is needed to
further determine this in the future study.
To our knowledge, this is the first study in which T-
SPOT.TB and TST were compared in ATB and LTB among
HIV-infected humans in BCG-vaccinated area. Recently,
Mandalakas and his colleagues have found that T-
SPOT.TB may have improved sensitivity for detection of
M. tuberculosis infection in HIV-infected individuals com-
pared to the QTF and the TST [24]. However, their study
was conducted in a setting highly endemic for TB in South
Africa, but not in routinely BCG-vaccinated area. There-
fore, the T-SPOT.TB assay appears more sensitive and spe-
cific for diagnosing both LTBI in HIV patients with history
of BCG vaccination and with confirmed active TB in our
study, indicating that the ELISPOT-based IFNGRA may be
a better tool for screening tuberculosis infection in China
as well as useful information for further implementation
of LTBI preventive treatment.
Positive rates of HIV+ individuals to ESAT-6/CFP-10 T- SPOT.TB and to TST, by CD4+ T cell count Figure 4
Positive rates of HIV+ individuals to ESAT-6/CFP-10 
T-SPOT.TB and to TST, by CD4+ T cell count. The 
black column represents the T-SPOT.TB positive rate, and 
the gray column represents TST positive rate. (a) Patients 
with active TB (group HIV+ATB). In subgroups of CD4+ T 
cells <200/μl and 200–500/μl, both P < 0.0001; (b) Individuals 
without active TB evidence (group HIV+LTB and HIV only). 
In subgroups of CD4+ T cells <200/μl and 200–500/μl, both 
P < 0.0001.
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Analysis in this study further confirmed that ELISPOT-
based IFNGRA was much more sensitive in patients with
lower CD4+ T cells level (<500/μl) than TST; T-SPOT.TB
assay was independent of CD4+ T cell counts as well as
history of BCG vaccination. Thus, it is evident that not
only active TB but also latent TB could be identified suc-
cessfully in HIV-infected people, providing solid basis to
screen latent TB individuals for implementing TB preven-
tive treatment.
Conclusion
In summary, ELISPOT-based IFNGRA is more sensitive
and specific than TST for TB diagnosis in Chinese HIV-
infected individuals and could be an effective tool for
guiding preventive treatment with isoniazid in latently
infected people and for TB control in China. A larger pro-
spective cohort study is needed to further confirm our
findings in the future.
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